🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Start of a new era here in the Dana-Farber CLL Center. First official clinic day for our newest CLL expert Inhye Ahn, MD. Welcome Dr. Ahn!

Delighted to share our latest paper in #JCO, in which we suggest an MRD growth model of CLL, including new data from the CLL14 study (Ven-Obi vs Clb-Obi). #leusm #GCLLSG ASCO Publications bit.ly/2ZyAVEZ Some results in a quick 🧵 1/n

Great end to an exciting #ASH21 conference with an amazing talk by Matthew Davids, MD, MMSc on therapies for p53 mutant hematologic malignancies - making inroads in an important area of unmet clinical need!

Check out our latest work on transcriptomic profiles of #CLL, drivers of MRD response and 5-year results from CLL14 – all out today in one paper Nature Communications : nature.com/articles/s4146… Key results in a brief 🧵

Big change to NCCN guidelines which now include pirtobrutinib for double exposed CLL pts - hopefully this helps with insurance coverage for pts who aren’t able to do clinical trials #cllsm

A reunion with Bloodbytes in International Conference on Malignant Lymphoma who was my attending during residency training—it was just a few years back :D

Thanks #DAVABermudaHeme for the chance to be part of this amazing meeting.

Excellent session at #iwCLL2023 on prevention of infection by Carsten Niemann, Clare Sun, Yair Yair Herishanu, Carolyn Owen, and Chris Pleyer. Going home with new and practical ideas on vaccination in #CLL.

What did we learn from the past decade with ibrutinib in #CLL? #NIH phase 2 study data presented by Dr. Adrian Wiestner showed: - Median PFS of 81 months for TN-CLL with TP53 alterations - Median PFS was even longer for TN-CLL without TP53 alterations - IGHV status matters.

Dr. Gulley @gulleyj1 talks about #Immunotherapy combination strategy at #AACR17. @NCICCR_MOS